Heart Failure study: NT-proBNP
Official title Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure
ClinicalTrials.gov ID: NCT05859048
What this study is testing
- What it's testing
- The study wants to see if using an electronic health record algorithm, a blood test called NT‑proBNP, and an AI‑based heart ultrasound can spot heart failure sooner than usual care.
- Who it's for
- Adults in Canada who are considered high risk for developing heart failure.
- What's involved
- Participants are randomly placed in usual care or the new screening group. The new group gets a blood draw for NT‑proBNP, and if the level is high, they receive an AI‑assisted heart ultrasound and a standard 12‑lead ECG within about four weeks.
- Time commitment
- The study follows participants for six months, with visits for the blood test, possible imaging, and routine record reviews.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Male or female \> 40 years of age
- Informed consent
- Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary...
- Diabetes type 1 or 2.
- Persistent or permanent atrial fibrillation.
You likely can't join if
- Inability to give informed consent (e.g. due to significant cognitive impairment).
- Previous diagnosis of heart failure. This is any diagnosis of heart failure with any ejection fraction of any cause.
- Renal replacement therapy.
- Anyone who, in the investigator's opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise...
See the full eligibility criteria
- Male or female \> 40 years of age
- Informed consent
- Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis or an epicardial coronary artery (50%...
- Diabetes type 1 or 2.
- Persistent or permanent atrial fibrillation.
- Previous ischemic or embolic stroke.
- Peripheral artery disease (previous surgical or percutaneous revascularization or documented stenosis \>50% of major peripheral arterial vessel.
- Chronic kidney disease (defined as an estimated glomerular filtration rate (eGFR)\ 300mg/g).
- Regular loop diuretic use for \>30 days within 12 months prior to consent.
- Chronic obstructive pulmonary disease (COPD) evidenced by one of the following: Pulmonary Function Test (PFT) showing airway obstruction, diagnosis of respiratory physician, CT scan reporting presence of emphysema, or...
- Inability to give informed consent (e.g. due to significant cognitive impairment).
- Previous diagnosis of heart failure. This is any diagnosis of heart failure with any ejection fraction of any cause.
- Renal replacement therapy.
- Anyone who, in the investigator's opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period.
The study team makes the final eligibility decision.
Where it is enrolling
- Vancouver, British Columbia, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Vancouver, British Columbia, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.